contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


optomed-oyj-optomeds-board-has-resolved-upon-a-new-option-plan-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

AEYE Health @linkedin: UCL’s research on the role of the LRG1 protein suggests that diabetes-induced retinal changes begin much earlier than previously thought. This elevates early screening to a whole new level. AI-based methods, such as AEYE-DS with portable cameras, can practically bring screening to primary healthcare and occupational health — where the majority of at-risk patients already are. The market is moving fast, and technology is clearly beginning to dictate how DR screening will be implemented in the future. Early detection is no longer an added benefit, but the new minimum.                   linkedin.com              Scientists pinpoint early trigger behind diabetic retinopathy - Insight |...    🩺 New research is changing how we think about diabetic retinopathy!  Scientists at University College London have identified a protein called LRG1 as the trigger for the earliest stages of diabetic retinopathy - long before symptoms appear. LRG1...

I didn’t find Lumon’s permit on the NMPA’s website, i.e., on the Chinese authorities’ website. If a permit has been obtained there, Optomed could have announced this. Apparently, that matter is also too small to be announced. Optomed Aurora has a permit. https://www.nmpa.gov.cn/datasearch/search-result.html Professional-looking website on that Chinese one.

lyqbq.com              欧视博免散瞳眼底照相机Optomed Lumo®-朗逸医疗-临时起搏器|眼科设备网站    欧视博（Optomed）Lumo® 免散瞳眼底照相机是一款兼具手持与固定使用模式的多功能成像设备，适用于多种医疗场景的眼底检查需求。                             Lumoa for the Chinese by a Shanghai dealer. The company is small, with about 50 employees, and its turnover is probably not very large. But of course, it could be soon.

The Greek police, “Hellenic Police”, has acquired and trained to use Aurora. Cameras will certainly continue to be encountered in the occupational health care of larger companies/organizations. From companies where employees and their health are valued and cared for.                   linkedin.com              #midimedical #sbmsistemi #os1000 #icare #ic100 #optomed #aurora...    MidiMedical successfully completed the supply, installation, and training for the new ophthalmic equipment systems at the medical offices of the Hellenic Police.  As part of the infrastructure upgrade, the following systems were installed:  • Sbm...

Well, what does that course matter anymore when according to that floodmap we are all already drowned here in Finland.  And half of the Sahara is under water too.

In 2011, there was a stock exchange release about a flood, but this year no announcement has been made, so probably those factories are fine for now. https://investor.fabrinet.com/news-releases/news-release-details/fabrinet-reports-impact-due-tosevere-flooding-thailand Manufacturer’s announcements can be found here: https://investor.fabrinet.com/financial-information/sec-filings

That worst water accumulation of over three meters seems to have occurred right in the southernmost province, which is quite a lot lower than where those production facilities are.

Optomed

Optomed Plc Stock Exchange Release 23 September 2025 at 9.00, HelsinkiOptomed's Board has resolved upon a new option planOptomed's board of directors has resolved upon a new option plan. The...

Optomed Plc&nbsp;Stock Exchange Release&nbsp;23 September 2025 at 9.00, HelsinkiOptomed's Board has resolved upon a new option planOptomed's board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 9 May 2025.&nbsp;Option plan 2025A:The total number of options is 190,000 and each option entitled to one share of the company. The options are offered to certain key employees. The purpose of the plan is to retain and incentifize the CEO and certain other key employees. The subscription price is EUR 3.77. The subscription price is based on the average closing prices of the last 30 trading days on Nasdaq Helsinki. The subscription period is 1 January 2027 - 31 December 2029. &nbsp;The theoretical market value of one option under the plan 2025A is approximately EUR 0.806 per stock option and the theoretical total market value of the plan 2025A is approximately 153,140 euros in total. The theoretical market value of a stock option has been calculated by using the Black &amp; Scholes stock option pricing model with the following input factors: share price EUR 3.69 euros, subscription price EUR 3.77 risk free interest rate 3.11%, validity of stock options approximately 3 years and volatility 47.4%.&nbsp;The complete terms and conditions of the option plan 2025A are attached to this release. Optomed Plc Further enquiriesPetri Salonen, Chairman, Optomed Plc, petri.salonen@optomed.com&nbsp;Optomed in Brief&nbsp;Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&amp;D in Finland and sales through different channels in over 60 countries. <a href="http://www.optomed.com">www.optomed.com</a> &nbsp;<div></div>